Related references
Note: Only part of the references are listed.Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Sara Pusceddu et al.
CANCERS (2019)
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
Junko Tahara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients
Yusuke Ogawa et al.
PANCREAS (2018)
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma
Benedetto Ielpo et al.
SURGICAL ONCOLOGY-OXFORD (2017)
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1
Soji Kakiuchi et al.
RESPIRATORY INVESTIGATION (2017)
A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine
Masahide Hiyoshi et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2017)
Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer
Aya Nakaya et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Yuki Nakatani et al.
CASE REPORTS IN ONCOLOGY (2017)
Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer
Takeshi Saito et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
Kohei Shitara et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Ken-Ichi Okada et al.
ANTICANCER RESEARCH (2017)
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Hideki Ueno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma
B. Ielpo et al.
EJSO (2016)
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2016)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
M. A. Socinski et al.
ANNALS OF ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
Osamu Matsuno
RESPIRATORY RESEARCH (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Circulating KL-6 levels in patients with drug induced pneumonitis
H Ohnishi et al.
THORAX (2003)